These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 16430468)
1. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. King JE; Thatcher N; Pickering CA; Hasleton PS Histopathology; 2006 Feb; 48(3):223-32. PubMed ID: 16430468 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Roberts F; Harper CM; Downie I; Burnett RA Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073 [TBL] [Abstract][Full Text] [Related]
4. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
5. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236 [TBL] [Abstract][Full Text] [Related]
6. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Riera JR; Astengo-Osuna C; Longmate JA; Battifora H Am J Surg Pathol; 1997 Dec; 21(12):1409-19. PubMed ID: 9414184 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Ordóñez NG Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414 [TBL] [Abstract][Full Text] [Related]
10. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496 [TBL] [Abstract][Full Text] [Related]
11. In search of a positive immunohistochemical marker for mesothelioma: an update. Ordóñez NG Adv Anat Pathol; 1998 Jan; 5(1):53-60. PubMed ID: 9868512 [No Abstract] [Full Text] [Related]
12. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557 [TBL] [Abstract][Full Text] [Related]
13. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584 [TBL] [Abstract][Full Text] [Related]
14. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Ordóñez NG Am J Surg Pathol; 2000 Apr; 24(4):598-606. PubMed ID: 10757409 [TBL] [Abstract][Full Text] [Related]
15. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123 [TBL] [Abstract][Full Text] [Related]
16. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Klebe S; Nurminen M; Leigh J; Henderson DW Pathology; 2009 Feb; 41(2):140-8. PubMed ID: 19152187 [TBL] [Abstract][Full Text] [Related]
18. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265 [TBL] [Abstract][Full Text] [Related]
19. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type. Comin CE; Dini S; Novelli L; Santi R; Asirelli G; Messerini L Am J Surg Pathol; 2006 Apr; 30(4):463-9. PubMed ID: 16625092 [TBL] [Abstract][Full Text] [Related]
20. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Oates J; Edwards C Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]